Targeting EBV-positive B- and T/NK-cell lymphomas

Heather Long

doi:10.1182/blood-2018-10-878587

Targeting EBV-positive B- and T/NK-cell lymphomas

Heather Long

Immunology and Immunotherapy

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).

Original language	English
Pages (from-to)	2315-2316
Number of pages	2
Journal	Blood
Volume	132
Issue number	22
DOIs	https://doi.org/10.1182/blood-2018-10-878587
Publication status	Published - 29 Nov 2018

Bibliographical note

Targeting EBV-positive B- and T/NK-cell lymphomas, Heather M. Long, Blood Nov 2018, 132 (22) 2315-2316; DOI: 10.1182/blood-2018-10-878587

Access to Document

10.1182/blood-2018-10-878587Licence: None: All rights reserved

Cite this

@article{ff1187733d4644cfbb27376572b2ee92,

title = "Targeting EBV-positive B- and T/NK-cell lymphomas",

abstract = "In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).",

author = "Heather Long",

note = "Targeting EBV-positive B- and T/NK-cell lymphomas, Heather M. Long, Blood Nov 2018, 132 (22) 2315-2316; DOI: 10.1182/blood-2018-10-878587",

year = "2018",

month = nov,

day = "29",

doi = "10.1182/blood-2018-10-878587",

language = "English",

volume = "132",

pages = "2315--2316",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Targeting EBV-positive B- and T/NK-cell lymphomas

AU - Long, Heather

N1 - Targeting EBV-positive B- and T/NK-cell lymphomas, Heather M. Long, Blood Nov 2018, 132 (22) 2315-2316; DOI: 10.1182/blood-2018-10-878587

PY - 2018/11/29

Y1 - 2018/11/29

N2 - In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).

AB - In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).

U2 - 10.1182/blood-2018-10-878587

DO - 10.1182/blood-2018-10-878587

M3 - Review article

SN - 0006-4971

VL - 132

SP - 2315

EP - 2316

JO - Blood

JF - Blood

IS - 22

ER -

Targeting EBV-positive B- and T/NK-cell lymphomas

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this